NOV 17, 2021 11:00 AM PST

FDA greenlights clinical trials for novel COVID-19 vaccine and delivery system

WRITTEN BY: J. Bryce Ortiz

Last week the United States Food and Drug Administration (FDA) authorized the biotechnology company Inovio to move forward with clinical trials in the United States to test their DNA-based plasmid COVID vaccine and new delivery system. This authorization is good news for the biotechnology company who is aiming to test its vaccine, called INO-4800, in conjunction with its delivery system called CELLECTRA 2000 in patients in the United States. The company is already performing clinical trials in several other countries. 

The FDA authorized the company to push forward with clinical trials after receiving new data on the delivery system. CELLECTRA 2000 is unique delivery system for vaccines. According to the company, the CELLECTRA device uses a series of brief electrical pulses to reversibly open small pores in cell membranes that allow for better penetrance of the company’s DNA-based vaccines. This activity of the device helps to overcome limitations of other DNA- or RNA-based vaccines. In clinical studies, researchers found that in healthy adults this method of vaccine delivery had minimal side effects and minimal pain with some mild side effects that resolved within one day. The data from this studies and others helped the FDA make its decision to approve the device for future clinical trials.

Inovio was also approved to move forward with clinical trials on its novel DNA-based Covid-19 vaccine, INO-4800. The vaccine is made up of a SARS-CoV-2 Spike DNA-based plasmid. This unique design allows the vaccine to provide immunity against variants of the SARS-CoV-2 virus including strains such as the delta variant. In a recent clinical trial, published in the journal npj Vaccines, researchers found that the INO-4800 vaccine induced neutralizing antibodies against all SARS-CoV-2 variants tested. Additionally, the vaccine had a similar safety and tolerability profile compared to other available COVID-19 vaccines. The clinical trial approval is another promising step in the progress of drug delivery and design researchers to help rid the world of COVID-19. 

 

Sources: Inovio NewsInovioHuman Vaccine ImmunotherapyeClinicalMedicine

About the Author
PhD in Neuroscience
Science and medical writer | Researcher | Interested in the intersection between translational science, drug development, and policy
You May Also Like
MAR 07, 2022
Drug Discovery & Development
The fight against dengue fever intensifies
MAR 07, 2022
The fight against dengue fever intensifies
Dengue fever is a serious and potentially life-threating illness, and remains on the World Health Organization&rsqu ...
MAR 25, 2022
Cannabis Sciences
Cannabis Product Consumer Choice Trends
MAR 25, 2022
Cannabis Product Consumer Choice Trends
A recent review of 35 cannabis consumer studies identified age, gender, and cannabis experiences as the main factors inf ...
MAR 29, 2022
Drug Discovery & Development
Nasal Spray Shows Promise Against All Variants of SARS-CoV-2
MAR 29, 2022
Nasal Spray Shows Promise Against All Variants of SARS-CoV-2
A compound delivered via a nasal spray can prevent and treat various COVID-19 variants in mice. The corresponding study ...
APR 11, 2022
Cancer
What is a Cancer Center?
APR 11, 2022
What is a Cancer Center?
Over 50 years ago, President Richard Nixon signed the National Cancer Act of 1971, a landmark piece of legislation ...
MAY 12, 2022
Cannabis Sciences
Cannabis Use Impacts Sleep Duration
MAY 12, 2022
Cannabis Use Impacts Sleep Duration
Frequency of cannabis use may be the reason some people get too little or too much sleep. A recent study published in th ...
MAY 11, 2022
Cannabis Sciences
Legal Recreational Cannabis Reduces Prescription Drug Demand
MAY 11, 2022
Legal Recreational Cannabis Reduces Prescription Drug Demand
A research study published in Health Economics found a link between the availability of legal recreational cannabis, and ...
Loading Comments...